INM
InMed Pharmaceuticals Inc.
NASDAQ · Healthcare · Biotechnology · CA
$1.38
+3.76%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 4.0M | 4.9M | 4.6M | 4.1M | 1.1M |
| Cost of Revenue | 2.8M | 3.2M | 3.5M | 2.7M | 545.9K |
| Gross Profit | 1.2M | 1.7M | 1.1M | 1.4M | 543.5K |
| Operating Expenses | |||||
| R&D Expense | 2.6M | 2.9M | 3.2M | 3.7M | 7.3M |
| SG&A Expense | 8.4M | 6.6M | 5.8M | 5.8M | 6.9M |
| General & Admin Expense | 8.4M | 6.6M | 5.8M | 5.8M | 6.9M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 104.9K | 212.8K | 219.6K | 202.2K | 185.7K |
| Total Operating Expenses | 11.2M | 9.6M | 9.2M | 9.8M | 14.3M |
| Cost and Expenses | 13.9M | 12.9M | 12.7M | 12.5M | 14.9M |
| Operating Income (EBIT) | (9.9M) | (7.9M) | (8.1M) | (8.4M) | (13.8M) |
| Non-Operating | |||||
| Interest Income | 295.3K | 156.5K | 722.0K | 652.4K | 123.7K |
| Interest Expense | 20.0K | 373.1K | — | — | — |
| Net Interest Income | 275.3K | (216.6K) | 722.0K | 652.4K | 123.7K |
| Other Non-Op Income/Expense | 189.8K | (244.1K) | 466.0K | 444.3K | (4.8M) |
| Non-Operating Income (excl Interest) | (116.5K) | (127.4K) | (466.0K) | (444.3K) | 4.8M |
| EBT (Pre-Tax Income) | (9.7M) | (8.2M) | (7.7M) | (7.9M) | (18.6M) |
| Income Tax Expense | — | — | 7.1K | 13.1K | — |
| Bottom Line | |||||
| Net Income | (9.9M) | (8.2M) | (7.7M) | (7.9M) | (18.6M) |
| Earnings from Cont. Ops | (9.7M) | (8.2M) | (7.7M) | (7.9M) | (18.6M) |
| Earnings from Discont. Ops | (174.6K) | — | — | — | — |
| Bottom Line Net Income | (9.9M) | (8.2M) | (7.7M) | (7.9M) | (18.6M) |
| Per Share | |||||
| Basic EPS | ($1,142.54) | ($8.36) | ($20.14) | ($64.92) | ($16,582.00) |
| Diluted EPS | ($1,142.54) | ($8.36) | ($20.14) | ($64.92) | ($16,582.00) |
| Revenue Per Share | $0.99 | $5.06 | $12.07 | $33.78 | $971.84 |
| Shares | |||||
| Basic Shares Outstanding | 4.0M | 975985 | 381053 | 122422 | 1121 |
| Diluted Shares Outstanding | 4.0M | 975985 | 381053 | 122422 | 1121 |
| Profitability Metrics | |||||
| EBITDA | (9.2M) | (7.3M) | (7.1M) | (7.3M) | (18.1M) |
| D&A | 578.8K | 534.7K | 604.5K | 596.0K | 511.8K |
| EBIT | (9.8M) | (7.8M) | (7.7M) | (7.9M) | (18.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026